Atherosclerosis and the Innate immune system in patients with Diabetes

Recruiting

Conditions: 10018424
arterial wall thickening
atherosclerosis
10003216

Registration Number: NL-OMON44284

Lead Sponsor: Academisch Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 640

Inclusion Criteria

Patients
- Aged 18 years or older
- Diagnosed with diabetes mellitus type 2 ;Control subjects
- Age 18 years or older
- No history of diabetes mellitus or impaired glucose tolerance
- No history of cardiovascular events
- No medication use

Exclusion Criteria

Exclusion criteria for all subjects
- Known malignant disorders or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator.
- Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
- History of cardiovascular event within the last 3 months.
- Clinical signs of acute infection and/or CRP > 10 mg/L.
- The use of chronic immunosuppressant drugs or antibiotics in the last 6 weeks.
- Chronic use of anti-inflammatory drugs.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>We will compare monocyte expression of pro-atherogenic markers, cytokine<br /><br>production, epigenetic changes and trans-endothelial migration between diabetes<br /><br>patients and controls, and asses differences between patient groups.<br /><br>Furthermore, changes in these parameters after ex vivo incubation with stimuli<br /><br>and current and novel anti-inflammatory therapies will be assessed. </p><br>

Secondary Outcome Measures